ProMetic announced this week that the next orphan indication to be investigated as part of its lead PBI-4050 small molecule programme would be cystic fibrosis (CF). The focus of the double-blind placebo-controlled phase II clinical trial will be on pancreatic fibrosis, glucose intolerance and diabetes in CF patients.
16 Dec 2015
PBI-4050 to target Cystic Fibrosis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
PBI-4050 to target Cystic Fibrosis
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
16 Dec 2015 -
Author:
Derren Nathan -
Pages:
7
ProMetic announced this week that the next orphan indication to be investigated as part of its lead PBI-4050 small molecule programme would be cystic fibrosis (CF). The focus of the double-blind placebo-controlled phase II clinical trial will be on pancreatic fibrosis, glucose intolerance and diabetes in CF patients.